- Home
- SUGP vs BCDA Comparison
SUGP vs BCDA Comparison
Compare SUGP & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- BCDA
- Stock Information
- Founded
- SUGP 1998
- BCDA N/A
- Country
- SUGP Hong Kong
- BCDA United States
- Employees
- SUGP N/A
- BCDA N/A
- Industry
- SUGP
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- BCDA Health Care
- Exchange
- SUGP NYSE
- BCDA Nasdaq
- Market Cap
- SUGP 9.6M
- BCDA 11.0M
- IPO Year
- SUGP 2024
- BCDA N/A
- Fundamental
- Price
- SUGP $0.50
- BCDA $2.15
- Analyst Decision
- SUGP
- BCDA Strong Buy
- Analyst Count
- SUGP 0
- BCDA 1
- Target Price
- SUGP N/A
- BCDA $25.00
- AVG Volume (30 Days)
- SUGP 146.6K
- BCDA 52.3K
- Earning Date
- SUGP 07-21-2025
- BCDA 08-12-2025
- Dividend Yield
- SUGP N/A
- BCDA N/A
- EPS Growth
- SUGP 1.19
- BCDA N/A
- EPS
- SUGP 0.11
- BCDA N/A
- Revenue
- SUGP $23,446,259.00
- BCDA $3,000.00
- Revenue This Year
- SUGP N/A
- BCDA N/A
- Revenue Next Year
- SUGP N/A
- BCDA N/A
- P/E Ratio
- SUGP $4.70
- BCDA N/A
- Revenue Growth
- SUGP 11.29
- BCDA N/A
- 52 Week Low
- SUGP $0.35
- BCDA $1.63
- 52 Week High
- SUGP $3.25
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- SUGP 34.00
- BCDA 51.13
- Support Level
- SUGP $0.47
- BCDA $1.98
- Resistance Level
- SUGP $0.66
- BCDA $2.45
- Average True Range (ATR)
- SUGP 0.08
- BCDA 0.17
- MACD
- SUGP -0.02
- BCDA 0.01
- Stochastic Oscillator
- SUGP 30.36
- BCDA 53.19
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).